Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is launching a Phase 3, multicenter, long-term study to evaluate the safety and efficacy of Abrocitinib in children aged 2 years and older with moderate-to-severe atopic dermatitis. This study, titled ‘A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema,’ aims to assess the long-term effects of Abrocitinib, with or without topical medications, over a 24-month period. The study is significant as it targets a pediatric population suffering from a chronic skin condition, potentially offering a new therapeutic option.
The intervention being tested is Abrocitinib, administered as a liquid oral suspension. This drug is intended to treat moderate-to-severe atopic dermatitis in children, providing a new approach to managing this condition.
The study is designed as an interventional, non-randomized, single-group assignment with no masking. Its primary purpose is treatment, focusing on the long-term safety and efficacy of Abrocitinib in the specified patient group.
The study is set to start on November 3, 2025, with an estimated completion date yet to be determined. The primary completion date is anticipated to align with the study’s 24-month duration or until commercial availability. The last update was submitted on July 8, 2025, indicating ongoing preparations for the study’s commencement.
This clinical study update could influence Pfizer’s stock performance positively by showcasing its commitment to expanding treatment options for pediatric patients with atopic dermatitis. Given the competitive landscape in dermatological treatments, successful outcomes could enhance Pfizer’s market position and investor confidence.
The study is currently not yet recruiting, with further details available on the ClinicalTrials portal.